<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="61911">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02299947</url>
  </required_header>
  <id_info>
    <org_study_id>NL45370.100.14</org_study_id>
    <nct_id>NCT02299947</nct_id>
  </id_info>
  <brief_title>Bloodtranfusions After Aortic Surgery</brief_title>
  <acronym>FIBTEG</acronym>
  <official_title>Comparison of a Single Dose Fibrinogen With Placebo and the Number of Blood Transfusions After Ascending Aorta Surgery (FIBTEG Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Antonius Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Antonius Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to answer the following question: Leads a primary coagulation
      corrected with a single dose of fibrinogen concentrate after ascending aorta-arc
      reconstruction to a decrease in the number of allogenic blood transfusions, compared to
      placebo?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiothoracic surgery (CTC) is associated with blood loss and an increased risk for
      impaired coagulation by the use of a CBP. Coagulation is a process of primary hemostasis by
      adhesion of trombocytes and aggregation, followed by secondary coagulation and fibrin
      formation. During CTC fibrinogen is the first coagulation factor which reaches critical
      concentration necessary for clotting. Point of Care clotting assay with thromboelastography
      (TEG) provides qualitative information on coagulation factors and clot strength. Specific
      coagulation factor correction of impaired clotting improves clot strength and may reduces
      the number of perioperative allogeneic blood transfusions, resulting in possible reduction
      of postoperative blood loss and reduction of the risk of re-operation in the short and long
      term. The hypothesis of this study is that a single dose fibrinogen concentrate immediately
      after CTC leads to a decrease in the number of allogenic blood transfusions in patients with
      clinically impaired clotting, verified by TEG.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of transfused blood products</measure>
    <time_frame>24 hours after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood loss</measure>
    <time_frame>24 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-operation</measure>
    <time_frame>30 day after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 day mortality</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Hemorrhage</condition>
  <condition>Thoracic Aneurysm</condition>
  <arm_group>
    <arm_group_label>Haemocomplettan P</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study patients that receive Haemocomplettan P</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NaCl 0.9%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Study patients that receive NaCl 0.9%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Haemocomplettan P</intervention_name>
    <arm_group_label>Haemocomplettan P</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>NaCl 0.9%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elective surgery for thoracic aneurysm

        Exclusion Criteria:

          -  Prior trombosis or myocardial infarction, congenital coagulation disorder, use of
             anti-coagulants prior to surgery, prior thoracic surgery, pregnancy, pre-operative
             fibrinogen concentration &lt;1g/L
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Noordzij, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Antonius Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eline Vlot</last_name>
    <email>e.vlot@antoniusziekenhuis.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>St Antonius hospital</name>
      <address>
        <city>Nieuwegein</city>
        <state>Utrecht</state>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Peter Noordzij, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 29, 2017</lastchanged_date>
  <firstreceived_date>November 18, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Antonius Hospital</investigator_affiliation>
    <investigator_full_name>dr. P. Noordzij</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Aortic Aneurysm, Thoracic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
